Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Jazz Pharma Plc
(NQ:
JAZZ
)
158.58
+2.57 (+1.65%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 1, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
387,954
Open
155.90
Bid (Size)
140.00 (1)
Ask (Size)
165.00 (2)
Prev. Close
156.01
Today's Range
153.96 - 159.28
52wk Range
117.64 - 186.22
Shares Outstanding
62,311,104
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
Top News
More News
What SVB Says On Axsome's Strategy Review On Sunosi For Sleeping Disorder
June 29, 2022
Axsome Therapeutics Inc (NASDAQ: AXSM) held an investor event to review its strategy with Sunosi, which is indicated for excessive daytime sleepiness (EDS) in narcolepsy and obstructive sleep apnea...
Via
Benzinga
Jazz Pharmaceuticals' Late-Stage Multiple Sclerosis Study Misses Primary Endpoint
June 28, 2022
Jazz Pharmaceuticals (NASDAQ: JAZZ) announced top-line results from the Phase 3 clinical trial investigating nabiximols oromucosal spray (JZP378) on clinical measures of spasticity in individuals with...
Via
Benzinga
Performance
YTD
+20.78%
+20.78%
1 Month
+7.48%
+7.48%
3 Month
-0.20%
-0.20%
6 Month
+24.47%
+24.47%
1 Year
-12.47%
-12.47%
More News
Read More
Jazz Pharma's Cannabidiol Mixture Spray Misses Primary Goal In Multiple Sclerosis Spasticity
June 28, 2022
Via
Benzinga
Switzerland Removes Medical Marijuana Access Limitations As Demand Rises
June 23, 2022
Via
Benzinga
This Pharmaceutical Company Is Moving Beyond CBD
June 23, 2022
Via
Benzinga
Jazz Pharma, Sumitomo Pharma Ink Licensing Pact For Sleeping Disorder Candidate
May 05, 2022
Via
Benzinga
Leisuretown: Diplo And Rob Dyrdek's New Cannabis Seltzers Launch In California Via Agreement With HERBL
June 23, 2022
Via
Benzinga
4 Analysts Have This to Say About Jazz Pharmaceuticals
June 14, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022
June 14, 2022
Via
Benzinga
Euro Food Agency Concerned About Health Effects Of CBD, Asks For More Research
June 10, 2022
Via
Benzinga
North Carolina House Says Yes To Bill Allowing FDA-Approved THC Drugs, Will This Kill Full Medical Marijuana Legalization?
June 09, 2022
Via
Benzinga
The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study
June 07, 2022
Via
Benzinga
FDA Battles Over CBD Hype Yet Again, This Time Warns Businesses Selling Illegal CBD For Food-Producing Animals
May 27, 2022
Via
Benzinga
Global Central Nervous System Treatment Market Is Expected to Reach $166 Billion In 2028
May 26, 2022
Via
FinancialNewsMedia
Exposures
COVID-19
Jazz Pharmaceuticals Stock Sees Rising Price Performance With Jump To 81 RS Rating
May 17, 2022
Via
Investor's Business Daily
Jazz Pharmaceuticals's Return On Capital Employed Insights
May 17, 2022
Via
Benzinga
What Does HC Wainwright Have To Say On Avadel's Narcolepsy Candidate's Potential Approval?
May 11, 2022
Via
Benzinga
Jazz Pharmaceuticals Completes U.S. Divestiture Of Sunosi To Axsome Therapeutics, What's Next?
May 09, 2022
Via
Benzinga
What 6 Analyst Ratings Have To Say About Jazz Pharmaceuticals
May 05, 2022
Via
Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
May 05, 2022
Via
Benzinga
Jazz Pharma Reports Q1 Epidiolex Sales Increased 6% To $157.9M YoY
May 05, 2022
Via
Benzinga
Jazz Pharmaceuticals: Q1 Earnings Insights
May 04, 2022
Via
Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
May 04, 2022
Via
Benzinga
EXCLUSIVE: Aurora Cannabis CEO 'Absolutely Confident' Company Will Be EBITDA-Positive By Year's End
April 20, 2022
Via
Benzinga
Axsome Therapeutics Stock Rockets As Its First FDA Approval Looks Imminent
April 19, 2022
Via
Investor's Business Daily
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.